Advertisement

Prevalence of antiphospholipid antibodies among patients with chronic thromboembolic pulmonary hypertension

  • Andrea Cervi
  • James Demetrios DouketisEmail author
IM - COMMENTARY

In most cases of acute pulmonary embolism, fibrinolysis of the embolus takes place, restoring blood flow and normalizing hemodynamic parameters. However, in a minority of patients, a residual organized clot remains adherent to the pulmonary vasculature which, over time, results in a progressive increase in pulmonary vascular resistance. This condition, known as chronic thromboembolic pulmonary hypertension (CTEPH), is a rare complication of pulmonary embolism that is characterized by the presence of persistent and organized thrombi in the proximal pulmonary arteries [1, 2]. Poor thrombus resolution due to inadequate fibrinolysis and/or recurrent thrombosis likely predispose towards the development of CTEPH. However, why only a small subset of patients go on to develop CTEPH following acute pulmonary embolism remains uncertain.

The classic hereditary thrombophilias, namely deficiencies in antithrombin, protein C and S, provide a plausible biologic basis for pulmonary vascular thrombus...

Notes

Compliance with ethical standards

Conflict of interest

Dr. Douketis reports receiving consulting fees or honouraria from Janssen, Pfizer, Sanofi, and Leo Pharma.

Statement on human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent is not required for this type of study.

References

  1. 1.
    Simonneau G, Torbicki A, Dorfmuller P, Kim N (2017) The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 26:143CrossRefGoogle Scholar
  2. 2.
    Cosmi B, Nijkeuter M, Valentino M et al (2011) Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med 6(6):521–528CrossRefGoogle Scholar
  3. 3.
    Wolf M, Boyer-Neumann C, Parent F et al (2000) Thrombotic risk factors in pulmonary hypertension. Eur Resp J 15:395–399CrossRefGoogle Scholar
  4. 4.
    Wong CL, Szydlo R, Gibbs S, Laffan M (2010) Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 21:201–206CrossRefGoogle Scholar
  5. 5.
    Park SY, Lee SM, Shin JW et al (2016) Epidemiology of chronic thromboembolic pulmonary hypertension in Korea: results from the Korean registry. Korean J Intern Med 31:305–312CrossRefGoogle Scholar
  6. 6.
    Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044CrossRefGoogle Scholar
  7. 7.
    Vargas-Hitos JA, Sabio JM, Navarrete-Navarrete N, Zamora-Pasadas M, Jimenez-Alonso J (2016) Severe digital necrosis as the clinical onset of antiphospholipid syndrome. Intern Emerg Med 11(5):761–762CrossRefGoogle Scholar
  8. 8.
    Bonderman D, Wilkens H, Wakounig S et al (2009) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Resp J 33:325–331CrossRefGoogle Scholar
  9. 9.
    Delcroix M, Kerr K, Fedullo P (2016) Chronic thromboembolic pulmonary hypertension. Epidemiology and risk factors. Ann Am Thorac Soc 13(Suppl 3):S201–S206CrossRefGoogle Scholar
  10. 10.
    Cheng CY, Zhang YX, Denas G, Du Y, Jing ZC, Pengo V (2019) Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-02021-z Google Scholar
  11. 11.
    Crowther MA, Kelton JG (2003) Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138:128–134CrossRefGoogle Scholar
  12. 12.
    Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365–1371CrossRefGoogle Scholar
  13. 13.
    Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010–2021CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Department of MedicineMcMaster University, St. Joseph’s Healthcare HamiltonHamiltonCanada

Personalised recommendations